Prostate

Disclaimer: This clinical reference provides general medical information for educational and informational purposes only, and does not constitute medical advice. It is not a substitute for professional medical judgment, diagnosis, or treatment. Clinicians must exercise their independent clinical judgment, consider individual patient circumstances, and refer to the most current evidence and guidelines. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to patient care.

Overview

• Definition: The prostate is a walnut-sized, exocrine gland of the male reproductive system, located inferior to the bladder and anterior to the rectum. It surrounds the prostatic urethra and its primary function is to secrete prostatic fluid, a component of semen that nourishes and protects sperm.
• Epidemiology:
  • Benign Prostatic Hyperplasia (BPH): Extremely common, affecting over 50% of men in their 60s and up to 90% of men in their 70s and 80s. Clinical symptoms occur in about half of these men.
  • Prostate Cancer (PCa): The most common non-skin cancer among men in Western countries and the second leading cause of cancer death in men. Approximately 1 in 8 men will be diagnosed with prostate cancer during their lifetime. Incidence increases significantly with age.
  • Prostatitis: Inflammatory conditions of the prostate. Prevalence is high, affecting up to 10-15% of men at some point in their lives.
• Classification:
  • Benign Prostatic Hyperplasia (BPH): Non-malignant enlargement of the prostate gland.
  • Prostate Cancer (PCa): Malignant neoplasm originating from the prostate gland, predominantly adenocarcinoma.
    • Localized: Cancer confined to the prostate gland.
    • Regionally advanced: Cancer extends beyond the prostate but not to distant sites.
    • Metastatic: Cancer has spread to distant sites (e.g., bone, lymph nodes, lungs).
  • Prostatitis: Classified into four main types by the NIH:
    • Category I: Acute Bacterial Prostatitis (ABP): Acute infection of the prostate.
    • Category II: Chronic Bacterial Prostatitis (CBP): Recurrent UTIs with persistent bacterial infection in the prostate.
    • Category III: Chronic Pelvic Pain Syndrome (CPPS): Chronic pain in the pelvic region without evidence of bacterial infection (further divided into IIIa inflammatory, and IIIb non-inflammatory).
    • Category IV: Asymptomatic Inflammatory Prostatitis: Inflammation of the prostate discovered incidentally (e.g., during biopsy for elevated PSA) without symptoms.

Pathophysiology

• Mechanism:
  • BPH: Pathogenesis is multifactorial but strongly age- and androgen-dependent. Dihydrotestosterone (DHT), converted from testosterone by 5-alpha reductase in prostate stromal cells, is a key growth stimulant. Over time, stromal and epithelial cell proliferation leads to nodule formation and glandular enlargement.
  • Prostate Cancer: Arises from uncontrolled growth of glandular cells within the prostate, driven by complex interactions of genetic, hormonal, and environmental factors. Androgen receptor signaling plays a crucial role in PCa development and progression. Mutations (e.g., BRCA2, HOXB13) and chromosomal alterations are implicated.
  • Prostatitis:
    • Bacterial (ABP, CBP): Typically caused by ascending infection from the urethra or reflux of infected urine into prostatic ducts. Common pathogens include E. coli and other Gram-negative bacteria.
    • CPPS: Etiology is unclear, thought to involve neurogenic inflammation, autoimmune processes, pelvic floor dysfunction, psychological factors, or infection with atypical organisms.
• Risk Factors:
  • BPH:
    • Age: Primary risk factor.
    • Androgens: Presence of functioning testes and normal testosterone levels.
    • Genetics: Family history of BPH (especially in younger men).
    • Obesity: May increase risk.
  • Prostate Cancer:
    • Age: Most significant risk factor; rare before age 40, risk increases sharply after 50.
    • Ethnicity: African American men have a higher incidence and mortality rate.
    • Genetics/Family History: First-degree relative (father, brother) with PCa, especially if diagnosed before age 65, doubles a man's risk. Specific gene mutations (e.g., BRCA1/2, HOXB13, Lynch syndrome).
    • Diet: High intake of red meat, high-fat dairy (less definitive evidence).
    • Environmental/Occupational: Exposure to certain chemicals (e.g., Agent Orange) may increase risk.
  • Prostatitis:
    • Bacterial: History of UTIs, unprotected anal intercourse, catheterization, prostate biopsy, structural abnormalities of the urinary tract.
    • CPPS: Stress, previous prostate infections, trauma, nerve damage.
• Protective Factors:
  • BPH/PCa (Less definitive evidence):
    • Diet: Regular consumption of vegetables (cruciferous), fruits, healthy fats (e.g., omega-3 fatty acids).
    • Lifestyle: Regular physical activity, maintaining a healthy weight.
    • Medications: 5-alpha reductase inhibitors (finasteride, dutasteride) reduce BPH progression and may reduce PCa incidence, but also increase risk of high-grade PCa (controversial for prevention).

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Lower Urinary Tract Symptoms (LUTS): Common to BPH and localized PCa.
    • Storage Symptoms (Irritative): Urinary frequency, urgency, nocturia.
    • Voiding Symptoms (Obstructive): Hesitancy, intermittency (stop-start voiding), weak stream, straining to void, prolonged voiding, incomplete bladder emptying, post-void dribbling.
  • Pain/Discomfort: Predominant symptom in prostatitis.
    • Acute Bacterial Prostatitis: Sudden onset of fever, chills, malaise, myalgia, dysuria, frequency, urgency, perineal/suprapubic pain.
    • Chronic Bacterial Prostatitis/CPPS: Chronic (≥3 months) pelvic pain (perineum, suprapubic, testicular, penile, low back), often associated with irritative voiding symptoms or ejaculatory pain/dysfunction.
• Early Signs:
  • BPH/Localized PCa: Mild LUTS (e.g., increased nocturia, slightly weaker stream). Often indistinguishable.
  • Prostatitis: Initial onset of dysuria, mild pelvic discomfort.
• Advanced Signs:
  • Prostate Cancer:
    • Local Progression: Gross hematuria (rare), acute urinary retention, hydronephrosis with renal insufficiency.
    • Metastatic Disease: Bone pain (especially back, pelvis), pathologic fractures, weight loss, fatigue, lower extremity edema (from lymph node involvement).
  • BPH: Severe LUTS progressing to acute urinary retention, recurrent UTIs, bladder calculi, hematuria, hydronephrosis.
• Atypical Presentations:
  • PCa: Rarely, paraneoplastic syndromes, disseminated intravascular coagulation.
  • Prostatitis: Sexual dysfunction (erectile dysfunction, premature ejaculation, painful ejaculation).

Physical Examination

• Inspection:
  • General: Look for signs of systemic illness (fever, chills in acute prostatitis; pallor, cachexia in advanced PCa).
  • Abdominal: Suprapubic tenderness, bladder distension (suggesting urinary retention).
  • Genital: Urethral discharge (suggesting urethritis, which can mimic prostatitis).
• Palpation:
  • Digital Rectal Exam (DRE): Essential for prostate evaluation.
    • Normal Prostate: Smooth, elastic, non-tender, bilobed, median sulcus palpable. Size is subjective (walnut-sized).
    • BPH: Symmetrically enlarged, smooth, firm, elastic, non-tender.
    • Prostate Cancer: Firm nodule(s), induration, asymmetry, loss of median sulcus, stony hard consistency (suggests advanced disease), fixed to rectal wall. Note: DRE has low sensitivity for early, localized PCa.
    • Acute Bacterial Prostatitis: Prostate is exquisitely tender, boggy, warm, and swollen. Caution: Vigorous massage or DRE should be avoided in acute bacterial prostatitis due to risk of bacteremia/sepsis.
    • Chronic Bacterial Prostatitis/CPPS: May be normal, mildly tender, or boggy.
  • Regional Lymph Nodes: Inguinal, supraclavicular for metastatic PCa.
• Special Tests: None specific for prostate in physical exam beyond DRE and general abdominal/genital assessment.

Diagnostic Approach

History Taking

• Key Questions:
  • Urinary Symptoms (LUTS): Quantify severity using a validated symptom score, such as the International Prostate Symptom Score (IPSS) or American Urological Association Symptom Index (AUA-SI). Inquire about onset, progression, bother, and impact on quality of life.
  • Pain: Location (perineum, suprapubic, testicular, penile, low back), character, intensity, duration, aggravating/alleviating factors.
  • Sexual Function: Erectile dysfunction, ejaculatory pain, decreased libido.
  • Systemic Symptoms: Fever, chills, fatigue, weight loss, night sweats (suggestive of infection, inflammation, or malignancy).
  • Past Medical History: UTIs, STIs, kidney stones, neurological conditions (e.g., diabetes, Parkinson's).
  • Medications: Any drugs affecting bladder function (e.g., decongestants, antihistamines, diuretics).
  • Surgical History: Previous prostate or bladder surgeries.
  • Family History: Prostate cancer in first-degree relatives, especially at a young age.
• Red Flags:
  • Acute urinary retention.
  • Gross hematuria (requires prompt urological evaluation).
  • New onset LUTS with systemic symptoms (fever, chills, weight loss).
  • Severe, unrelenting bone pain (suggests metastatic PCa).
  • Neurological deficits (suggests spinal cord compression from metastatic PCa).
  • Elevated creatinine or signs of renal insufficiency (suggests obstruction).
  • Abnormal DRE (nodule, induration).
  • Rapidly rising PSA.

Laboratory Tests

• First-Line:
  • Urinalysis (UA) with Culture & Sensitivity (UCx): Essential to rule out UTI, microscopic hematuria. Positive in acute/chronic bacterial prostatitis. Negative in BPH, PCa, CPPS.
  • Prostate-Specific Antigen (PSA):
    • Purpose: A glycoprotein produced by prostatic epithelial cells. Used for prostate cancer screening, diagnosis, staging, and monitoring.
    • Normal Range: Generally < 4.0 ng/mL, but age-adjusted ranges are often used. PSA is a continuous variable, and risk increases with increasing PSA.
    • Limitations: Not cancer-specific; can be elevated in BPH, prostatitis, recent DRE, ejaculation, catheterization. High sensitivity but low specificity for PCa.
  • Serum Creatinine/BUN: To assess renal function, especially with obstructive symptoms.
• Confirmatory:
  • PSA Derivatives:
    • Free PSA/Total PSA Ratio: In men with total PSA 4-10 ng/mL, a lower free/total PSA ratio (< 0.15-0.25) suggests a higher risk of PCa.
    • PSA Velocity: Rate of change of PSA over time. A rise > 0.75 ng/mL/year may increase suspicion.
    • PSA Density: PSA divided by prostate volume (from TRUS). A higher density (> 0.15 ng/mL/cm³) increases suspicion.
    • Prostate Health Index (PHI): A multianalyte blood test combining total PSA, free PSA, and p2PSA (a proenzyme form of PSA) to improve PCa detection specificity.
  • Fractionated Urine for Prostatitis (Meares-Stamey Test): Localizes infection to the urethra, bladder, or prostate. Involves collecting four urine samples (initial voided urine, midstream urine, expressed prostatic secretions after massage, post-massage voided urine). Positive bacterial counts in EPS or post-massage urine compared to pre-massage urine indicate prostatitis.
• Monitoring:
  • PSA: Post-treatment surveillance for PCa (e.g., after radical prostatectomy, radiation, or during active surveillance). Every 3-6 months initially, then annually.
  • Testosterone: During androgen deprivation therapy for PCa.
  • UA/UCx: For recurrent UTIs in chronic prostatitis.

Imaging

• Recommended:
  • Transrectal Ultrasound (TRUS):
    • Purpose: Primarily used for prostate volume measurement (for BPH or PSA density calculation) and as guidance for prostate biopsy.
    • Findings: Can visualize hypoechoic lesions suspicious for PCa, but has low sensitivity and specificity as a primary diagnostic tool.
  • Renal/Bladder Ultrasound:
    • Purpose: To assess for hydronephrosis (upper tract obstruction), bladder wall thickening, bladder calculi, and to measure post-void residual (PVR) urine volume.
    • PVR: A PVR > 50-100 mL is often considered significant in patients with LUTS.
  • Uroflowmetry: Non-invasive test measuring urine flow rate and pattern. Reduced peak flow rate (Qmax < 10-15 mL/s) suggests obstruction.
• Advanced:
  • Multiparametric MRI (mpMRI) of the Prostate:
    • Purpose: Becoming standard for PCa diagnosis, staging, and biopsy guidance. Combines T2-weighted imaging, diffusion-weighted imaging (DWI), and dynamic contrast-enhanced (DCE) imaging.
    • Findings: Can identify suspicious lesions using PI-RADS (Prostate Imaging Reporting and Data System) scoring. Highly sensitive for clinically significant PCa, can help target biopsies.
  • CT Scan (Abdomen/Pelvis): Primarily used for staging of high-risk PCa to detect lymphadenopathy or distant metastases.
  • Bone Scan (Technetium-99m bone scintigraphy): Performed in men with high-risk PCa (e.g., PSA > 20 ng/mL, Gleason score ≥ 8, or T-stage T3-4) or symptoms of bone pain to detect skeletal metastases.
  • PSMA PET/CT (Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography): Highly sensitive for detecting prostate cancer metastases, especially in biochemical recurrence after definitive treatment and in high-risk localized disease. Increasingly used for staging and restaging.

Management

Acute Management

• Immediate:
  • Acute Urinary Retention (AUR):
    • Catheterization: Urethral catheter (Foley) for immediate decompression. If unable to pass, consideration of suprapubic catheter.
    • Alpha-blocker: Initiate an alpha-adrenergic blocker (e.g., tamsulosin 0.4 mg daily) after catheter insertion to relax prostatic smooth muscle and improve subsequent voiding.
  • Acute Bacterial Prostatitis (ABP): Initiate empiric broad-spectrum antibiotics (e.g., fluoroquinolone like ciprofloxacin 500 mg BID or levofloxacin 500 mg daily) immediately, particularly if febrile or systemically unwell, prior to culture results.
• Stabilization:
  • ABP: IV antibiotics for severe cases or sepsis. Analgesics and antipyretics for symptom control. Hydration.
  • AUR: Monitor voiding function after catheter removal (trial without catheter - TWOC).
• Emergency:
  • Sepsis secondary to ABP: IV fluids, broad-spectrum IV antibiotics, vasopressors as needed, ICU admission.
  • Acute Renal Failure from Obstruction: Urgent urological consultation for drainage (catheterization or nephrostomy).

Chronic Management

Pharmacological

• Benign Prostatic Hyperplasia (BPH):
  • Alpha-1 Adrenergic Blockers: (e.g., tamsulosin 0.4 mg daily, alfuzosin 10 mg daily, silodosin 8 mg daily, doxazosin 4-8 mg daily, terazosin 5-10 mg daily).
    • Mechanism: Relax smooth muscle in the prostate and bladder neck, reducing dynamic obstruction.
    • Onset: Rapid (days to weeks).
    • Side Effects: Orthostatic hypotension (more common with non-uroselective agents like doxazosin/terazosin), dizziness, retrograde ejaculation (tamsulosin, silodosin).
  • 5-alpha Reductase Inhibitors (5-ARIs): (e.g., finasteride 5 mg daily, dutasteride 0.5 mg daily).
    • Mechanism: Inhibit the conversion of testosterone to DHT, leading to prostate gland shrinkage (typically 20-30%) and reduction in PSA (approx. 50%).
    • Onset: Slow (6-12 months for maximal effect).
    • Indications: For men with larger prostates (>30-40 mL) and significant LUTS, or those at risk of BPH progression.
    • Side Effects: Decreased libido, erectile dysfunction, ejaculatory dysfunction, gynecomastia.
  • Combination Therapy: Alpha-blocker + 5-ARI (e.g., tamsulosin + dutasteride).
    • Indications: Recommended for men with larger prostates, higher PSA, and more severe symptoms. More effective than monotherapy in preventing BPH progression and AUR.
  • Anticholinergics/Beta-3 Agonists: (e.g., solifenacin 5-10 mg daily, mirabegron 25-50 mg daily).
    • Indications: For men with predominant storage symptoms (urgency, frequency, nocturia), often combined with alpha-blockers if obstructive symptoms are also present and PVR is low.
    • Contraindication: High PVR due to risk of AUR.
  • PDE5 Inhibitors: (e.g., tadalafil 5 mg daily).
    • Mechanism: May improve LUTS by relaxing smooth muscle in the bladder and prostate.
    • Indications: For men with both LUTS and erectile dysfunction.
• Prostatitis:
  • Acute Bacterial Prostatitis (ABP):
    • Antibiotics: Fluoroquinolones (ciprofloxacin, levofloxacin) or trimethoprim-sulfamethoxazole (TMP-SMX) for 4-6 weeks to ensure penetration into prostatic tissue.
  • Chronic Bacterial Prostatitis (CBP):
    • Antibiotics: Prolonged course (6-12 weeks) of fluoroquinolones or TMP-SMX guided by culture.
  • Chronic Pelvic Pain Syndrome (CPPS):
    • Alpha-blockers: (e.g., tamsulosin) for men with obstructive symptoms or voiding dysfunction (4-6 weeks trial).
    • Antibiotics: Short course (2-4 weeks) often tried empirically, but long-term use not indicated if cultures negative.
    • NSAIDs: (e.g., ibuprofen, naproxen) for pain and inflammation.
    • Neuropathic Pain Agents: (e.g., gabapentin, pregabalin, amitriptyline) for chronic pain.
    • Muscle Relaxants: (e.g., cyclobenzaprine, diazepam) for pelvic floor spasm.
• Prostate Cancer (PCa): Management depends on stage, grade, patient age, and comorbidities.
  • Localized PCa (low/favorable intermediate risk):
    • Active Surveillance (AS): Monitoring with serial PSA, DRE, and repeat biopsies (often guided by mpMRI). Criteria: Low-risk (Gleason 3+3=6, PSA <10, clinical stage T1c/T2a) or favorable intermediate-risk PCa. Aims to avoid or delay aggressive treatment side effects.
    • Radical Prostatectomy: Surgical removal of the prostate gland and seminal vesicles. Can be open, laparoscopic, or robot-assisted.
    • Radiation Therapy: External Beam Radiation Therapy (EBRT) or Brachytherapy (implantation of radioactive seeds).
  • Locally Advanced PCa (unfavorable intermediate/high risk): Often involves multi-modality treatment.
    • EBRT ± Androgen Deprivation Therapy (ADT): ADT (LHRH agonists/antagonists) for 6 months to 3 years.
    • Radical Prostatectomy ± Lymph Node Dissection ± ADT.
  • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC):
    • Androgen Deprivation Therapy (ADT): Primary treatment.
      • Luteinizing Hormone-Releasing Hormone (LHRH) Agonists: (e.g., leuprolide, goserelin) cause initial testosterone flare, then downregulation of LH/FSH, leading to castrate levels of testosterone.
      • LHRH Antagonists: (e.g., degarelix) block LHRH receptors, causing rapid reduction in testosterone without a flare.
      • Bilateral Orchiectomy: Surgical castration, rapid and permanent.
    • Androgen Receptor Pathway Inhibitors (ARPIs): (e.g., abiraterone acetate + prednisone, enzalutamide) significantly improve survival when added to ADT.
    • Chemotherapy: (e.g., docetaxel) in combination with ADT improves survival in high-volume mHSPC.
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC): Progression of PCa despite castrate levels of testosterone.
    • ARPIs: (e.g., abiraterone + prednisone, enzalutamide, apalutamide, darolutamide).
    • Chemotherapy: (e.g., docetaxel, cabazitaxel).
    • Immunotherapy: (e.g., pembrolizumab for MSI-high/dMMR or HRR gene-mutated mCRPC).
    • Radiopharmaceuticals: (e.g., Radium-223 for bone metastases, Lutetium-177 PSMA for PSMA-positive mCRPC).
    • PARP Inhibitors: (e.g., olaparib, rucaparib) for men with BRCA1/2 or other homologous recombination repair gene mutations.

Non-pharmacological

• BPH:
  • Lifestyle Modifications: Avoidance of caffeine and alcohol, especially before bedtime; timed voiding; double voiding; pelvic floor exercises; fluid restriction in the evening; avoiding medications that worsen LUTS (e.g., anticholinergics, decongestants).
  • Minimally Invasive Surgical Therapies (MIST):
    • Urolift (Prostatic Urethral Lift): Permanent implants pull prostatic tissue away from the urethra.
    • Rezum (Water Vapor Thermal Therapy): Convective water vapor thermal energy ablates prostatic tissue.
  • Surgical Interventions:
    • Transurethral Resection of the Prostate (TURP): Gold standard for surgical management of BPH. Resection of obstructing prostate tissue.
    • Photoselective Vaporization of the Prostate (PVP) / Holmium Laser Enucleation of the Prostate (HoLEP): Laser-based procedures, often with less bleeding risk.
    • Open Prostatectomy: For very large prostates (>80-100 g).
• Prostatitis:
  • Acute Bacterial Prostatitis: Rest, hydration, stool softeners, sitz baths.
  • Chronic Bacterial Prostatitis/CPPS:
    • Dietary Modifications: Avoidance of caffeine, alcohol, spicy foods, acidic foods that irritate the bladder.
    • Sitz Baths/Heat Therapy: For symptomatic relief.
    • Pelvic Floor Physical Therapy: Biofeedback, manual therapy to release trigger points or hypertonic pelvic floor muscles.
    • Stress Reduction Techniques: Mindfulness, meditation.
    • Acupuncture: May provide relief for some patients with CPPS.
• Prostate Cancer:
  • Watchful Waiting: For men with very limited life expectancy and low-risk disease, with palliative intent.
  • Lifestyle: Healthy diet, regular exercise, weight management (limited direct evidence for cancer progression but general health benefit).

Monitoring

• BPH:
  • Annual follow-up: Assessment of LUTS (IPSS), PVR, uroflowmetry. Re-evaluate treatment effectiveness and side effects.
• Prostate Cancer:
  • Active Surveillance: PSA and DRE every 3-6 months, repeat mpMRI annually, confirmatory biopsy at 12 months, then periodically (e.g., every 2-5 years).
  • Post-Treatment Surveillance:
    • Radical Prostatectomy: PSA every 3-6 months for 2-3 years, then annually. PSA should be undetectable (<0.1-0.2 ng/mL).
    • Radiation Therapy: PSA every 3-6 months for 2-3 years, then annually. PSA typically declines over time but may not reach undetectable levels. Nadir + 2.0 ng/mL is often considered biochemical recurrence.
  • Advanced PCa: PSA, testosterone, imaging (CT, bone scan, PSMA PET) as indicated to monitor disease progression and treatment response.

Treatment Algorithms

• First-Line:
  • BPH:
    1. Mild Symptoms (IPSS < 8): Watchful waiting, lifestyle modifications.
    2. Moderate-Severe Symptoms (IPSS ≥ 8): Alpha-blockers.
  • Acute Bacterial Prostatitis: Empiric oral antibiotics (fluoroquinolone or TMP-SMX) for 4-6 weeks.
  • Localized Low-Risk PCa (Gleason 3+3=6, PSA < 10, T1c/T2a): Active surveillance.
  • Localized Intermediate/High-Risk PCa: Radical prostatectomy or Radiation therapy with or without ADT.
• Second-Line:
  • BPH:
    1. Insufficient response to alpha-blocker: Add 5-ARI (for larger prostates) or switch to combination therapy.
    2. Predominant storage symptoms with low PVR: Add anticholinergic/beta-3 agonist.
    3. Significant bother/refractory LUTS despite medical therapy: Minimally invasive surgical therapies (Urolift, Rezum).
  • Chronic Bacterial Prostatitis: Prolonged antibiotic course (6-12 weeks) based on culture, alpha-blockers.
  • CPPS: Alpha-blockers, NSAIDs, pelvic floor physical therapy, dietary changes.
  • Metastatic Hormone-Sensitive PCa (mHSPC): ADT + ARPI (abiraterone, enzalutamide) or chemotherapy (docetaxel).
• Refractory Cases:
  • BPH:
    1. Failed medical/MIST: Transurethral Resection of Prostate (TURP) or other surgical options (PVP, HoLEP, open prostatectomy).
    2. Recurrent AUR, renal impairment, bladder stones: Surgical intervention.
  • Chronic Prostatitis/CPPS: Multimodal approach involving pain specialists, urology, physical therapy, psychology. Consider neuromodulation, prostate massage (controversial), alternative therapies.
  • Metastatic Castration-Resistant PCa (mCRPC): Sequential use of ARPIs, chemotherapy, radiopharmaceuticals, PARP inhibitors, immunotherapy based on prior treatments, mutations, and PSMA status. Palliative care is critical.

Complications

• Common:
  • BPH: Acute urinary retention, urinary tract infections, hematuria, bladder stones, post-surgical ejaculatory dysfunction (retrograde ejaculation), erectile dysfunction.
  • PCa Treatments: Erectile dysfunction, urinary incontinence, bowel dysfunction, fatigue, hot flashes (from ADT), bone loss (from ADT).
  • Prostatitis: Recurrent UTIs, epididymitis, sexual dysfunction, chronic pelvic pain.
• Serious:
  • BPH: Hydronephrosis leading to renal failure, bladder diverticula.
  • PCa: Metastatic disease (bone fractures, spinal cord compression), uremia from ureteral obstruction, death.
  • Acute Bacterial Prostatitis: Sepsis, prostatic abscess formation.
• Long-term:
  • BPH: Progressive LUTS, need for surgery.
  • PCa: Chronic pain, persistent sexual dysfunction, urinary incontinence (post-prostatectomy), psychological distress, treatment-induced secondary malignancies (rare).
  • Prostatitis: Chronic pain, depression, anxiety, reduced quality of life.

Prognosis

• Factors:
  • BPH: Largely benign course, but progression risk (AUR, surgery) correlated with age, baseline PSA, prostate volume, and symptom severity.
  • Prostate Cancer:
    • Stage: Most important prognostic factor. Localized disease has excellent prognosis.
    • Gleason Score: Reflects tumor aggressiveness. Lower score (e.g., 3+3=6) indicates less aggressive, higher score (e.g., 4+5=9) indicates more aggressive.
    • PSA Level: Higher pre-treatment PSA correlates with higher risk of recurrence and metastasis.
    • Genomic Risk Scores: Increasingly used to stratify risk in localized disease (e.g., Oncotype DX, Decipher).
    • Age and Comorbidities: Impact treatment options and overall survival.
  • Prostatitis:
    • Acute Bacterial Prostatitis: Excellent prognosis with appropriate antibiotic treatment.
    • Chronic Bacterial Prostatitis: Can be challenging to eradicate, with recurrence common.
    • CPPS: Highly variable, often chronic and relapsing-remitting. Significant impact on quality of life.
• Survival:
  • BPH: Does not directly impact mortality.
  • Prostate Cancer:
    • Localized PCa: 5-year relative survival approaches 100%. 15-year survival rates are also very high, emphasizing that many men "live with" prostate cancer rather than "die from" it.
    • Regional PCa: 5-year relative survival ~90%.
    • Metastatic PCa: 5-year relative survival ~34%, significantly improved with modern systemic therapies.
• Quality of Life:
  • BPH: LUTS can significantly impair quality of life; successful treatment improves this.
  • PCa: Treatment-related side effects (ED, incontinence, bowel dysfunction, ADT side effects) significantly impact QoL. Active surveillance aims to preserve QoL.
  • Prostatitis: Chronic pain can be debilitating, leading to psychological distress and reduced QoL.

Prevention

• Primary: Preventing initial occurrence.
  • Lifestyle: Maintain a healthy weight, regular physical activity, balanced diet rich in fruits, vegetables, and whole grains (limited definitive evidence for PCa prevention, but good for overall health).
  • Dietary Supplements: No clear evidence supports the use of specific vitamins (e.g., vitamin E, selenium) or supplements for PCa prevention, and some may be harmful (e.g., high-dose vitamin E).
  • 5-ARIs (Finasteride/Dutasteride): Have shown to reduce the incidence of PCa in large trials but also increased the risk of high-grade PCa in some studies. Not routinely recommended for PCa prevention.
• Secondary: Early detection and intervention.
  • Prostate Cancer Screening:
    • PSA and DRE: Screening remains controversial. Shared decision-making between clinician and patient is paramount.
    • Guidelines (e.g., AUA, NCCN, USPSTF):
      • AUA: Recommend offering screening to men aged 55-69 years after discussion of benefits and harms. Against routine screening for men <40 or >70 with average risk.
      • USPSTF: Recommends individualized decision-making for men aged 55-69 years (Grade C). Recommends against screening for men 70 years or older (Grade D).
      • High-Risk Groups: Screening may start earlier (e.g., age 40-45) for African American men or those with a strong family history.
• Tertiary: Preventing complications.
  • BPH: Early treatment of LUTS can prevent acute urinary retention, recurrent UTIs, and potential renal damage.
  • Prostate Cancer: Active surveillance for low-risk disease to avoid overtreatment side effects. Timely treatment of localized disease to prevent metastasis. Palliative care for advanced disease to manage symptoms and improve QoL.

Special Populations

• Geriatric:
  • High Prevalence: BPH and PCa are highly prevalent in older men.
  • Comorbidities: Polypharmacy, cardiovascular disease, diabetes, cognitive impairment are common. Treatments must be tailored, considering drug interactions and side effect burden.
  • Functional Status: Treatment decisions for PCa should consider life expectancy (co-morbidities rather than chronologic age) and functional status. Active surveillance or watchful waiting often preferred for older, frail men with low-risk localized PCa.
  • BPH: Alpha-blockers may exacerbate orthostatic hypotension. Anticholinergics can worsen cognitive function.
• Comorbidities:
  • Cardiovascular Disease: Caution with alpha-blockers due to hypotension. LHRH agonists for PCa can increase cardiovascular risk (monitor for dyslipidemia, diabetes).
  • Renal Insufficiency: Adjust antibiotic dosages for prostatitis. Manage obstructive uropathy promptly.
  • Diabetes: Can contribute to neurogenic bladder and worsen LUTS.
  • Obesity: Associated with increased risk of aggressive PCa and higher rates of treatment complications.

Clinical Pearls

• Diagnostic:
  • PSA is not prostate cancer-specific. Always interpret PSA in context of age, DRE findings, family history, and other factors (recent ejaculation, infection, instrumentation). A significantly elevated PSA (>10 ng/mL) warrants further investigation regardless of other factors.
  • A negative DRE does not rule out PCa, especially for early or anteriorly located tumors.
  • Always perform a urinalysis in men presenting with LUTS or suspected prostatitis to rule out infection.
  • Avoid vigorous DRE in suspected acute bacterial prostatitis due to risk of bacteremia.
  • mpMRI is increasingly important for guiding biopsy and risk stratification in men with elevated PSA. Consider it before a first biopsy or before re-biopsy if prior biopsies were negative but suspicion remains.
• Treatment:
  • Shared decision-making is crucial for PCa screening and treatment. Inform patients of benefits, harms, and uncertainties.
  • Alpha-blockers work quickly for BPH, while 5-ARIs take months to show effect but can prevent BPH progression.
  • For BPH with severe LUTS and large prostate, combination therapy (alpha-blocker + 5-ARI) is often superior to monotherapy.
  • Chronic Pelvic Pain Syndrome management is often multidisciplinary and requires patience. Manage expectations for complete resolution.
  • ADT for PCa has significant side effects (hot flashes, fatigue, sexual dysfunction, bone loss, metabolic changes). Counsel patients thoroughly and manage these proactively.
• Pitfalls:
  • Over-reliance on PSA alone: Can lead to unnecessary biopsies or missed diagnoses.
  • Over-treatment of indolent PCa: Active surveillance is a valid and often preferred option for low-risk disease.
  • Under-treatment of acute bacterial prostatitis: Inadequate duration of antibiotics can lead to chronic infection or abscess.
  • Misinterpreting LUTS: LUTS can be caused by conditions other than BPH (e.g., overactive bladder, urethral stricture, neurological conditions).
  • Ignoring patient preferences: Treatment choices, especially for PCa, should align with patient values regarding quality of life versus cancer control.

Recent Updates

• Guidelines:
  • USPSTF 2018 recommendations emphasize individualized decision-making for PSA screening in men aged 55-69, with a shift away from routine screening.
  • AUA and EAU guidelines continue to refine criteria for active surveillance in low-risk and favorable intermediate-risk PCa, incorporating mpMRI findings.
  • NCCN Guidelines updated regularly to reflect new systemic therapies for metastatic hormone-sensitive and castration-resistant PCa (e.g., earlier use of ARPIs and chemotherapy).
• Evidence:
  • Role of mpMRI: Strong evidence supports the use of mpMRI prior to biopsy in men with suspected PCa, improving detection of clinically significant cancers and reducing detection of indolent disease.
  • Novel Systemic Therapies: Continued development and approval of new agents (e.g., enzalutamide, apalutamide, darolutamide, PARP inhibitors, PSMA-targeted radioligand therapy) have significantly improved survival for advanced PCa.
  • MIST for BPH: Growing evidence for the efficacy and durability of minimally invasive surgical therapies (e.g., Urolift, Rezum) as alternatives to medical therapy or TURP for specific patient populations.
• Controversies:
  • PSA Screening: Ongoing debate regarding the optimal age to start and stop screening, frequency, and which men truly benefit.
  • Optimal treatment for intermediate-risk PCa: The best approach (surgery, radiation, or active surveillance) for favorable and unfavorable intermediate-risk localized PCa remains an area of active research.
  • Role of prophylactic antibiotics for prostate biopsy: While traditionally given, evidence suggests that targeted prophylaxis based on local resistance patterns or rectal swab cultures may be superior to routine empiric prophylaxis.

Key References

• Guidelines:
  • American Urological Association (AUA) Guidelines (e.g., on BPH, Prostate Cancer, Prostatitis, PSA)
  • European Association of Urology (EAU) Guidelines (e.g., on BPH, Prostate Cancer, Chronic Pelvic Pain)
  • National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer
  • U.S. Preventive Services Task Force (USPSTF) Recommendation Statement on Prostate Cancer Screening
• Studies:
  • PLESS Study (Prostate Long-term Efficacy and Safety Study): Landmark study on finasteride for BPH.
  • MTOPS Study (Medical Therapy of Prostatic Symptoms): Provided evidence for combination therapy in BPH.
  • PROTECT, PIVOT, SPCG-4 Trials: Large randomized controlled trials comparing radical prostatectomy, radiation therapy, and watchful waiting for localized prostate cancer.
  • STAMPEDE, CHAARTED, LATITUDE, TITAN Trials: Pivotal trials establishing the role of ARPIs and chemotherapy in metastatic hormone-sensitive prostate cancer.
  • PROfound, TRITON2, CARD Trials: Trials supporting PARP inhibitors and cabazitaxel in mCRPC.
• Reviews:
  • UpToDate: Comprehensive clinical reviews on all aspects of prostate diseases.
  • Harrison's Principles of Internal Medicine: For pathophysiology and general medical context.
  • Campbell-Walsh Urology: Definitive textbook for urological conditions.